(Q35873740)

10 August 2017

1 reference

title

Safety and side effect profile of fluoxetine (English)

1 reference

10 August 2017

Joachim F Wernicke

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Expert Opinion on Drug Safety

10 August 2017

published in

1 reference

10 August 2017

volume

3

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

495-504

1 reference

Pregnancy and renal failure: the case for application of dosage guidelines

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Benefits and risks to mother and infant of drug treatment for postnatal depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Weight gain in infants breastfed by mothers who take fluoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Cardiovascular effects of fluoxetine in depressed patients with heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Blood pressure changes during short-term fluoxetine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Mortality and poststroke depression: a placebo-controlled trial of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Mechanism of action of St John's wort in depression : what is known?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Drug interactions between herbal and prescription medicines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Interactions between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Clinically significant drug interactions with antidepressants in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Antiarrhythmic agents: drug interactions of clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Antidepressant discontinuation syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.495

21 January 2018

Identifiers

DOI

10.1517/14740338.3.5.495

1 reference

10 August 2017

1 reference